Pasithea Therapeutics Corp (KTTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) has a cash flow conversion efficiency ratio of -0.237x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($12.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Pasithea Therapeutics Corp to measure how much of total assets are equity-financed.
Pasithea Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Pasithea Therapeutics Corp's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Pasithea Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pasithea Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ENTYR Ltd
AU:ETR
|
0.167x |
|
Wira Global Solusi Tbk PT
JK:WGSH
|
0.021x |
|
Ryvyl Inc
NASDAQ:RVYL
|
0.948x |
|
All In FutureTech Alliance Inc.
NASDAQ:AIFA
|
-0.020x |
|
Baillie Gifford US Growth Trust PLC
LSE:USA
|
-0.004x |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
0.015x |
|
LDT Inc
KQ:096870
|
0.027x |
|
Yummy Town Cayman Holdings
TWO:2726
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual cash flow conversion efficiency of Pasithea Therapeutics Corp from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Pasithea Therapeutics Corp market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.78 Million | $-13.92 Million | -0.942x | -64.15% |
| 2023-12-31 | $23.40 Million | $-13.43 Million | -0.574x | -78.10% |
| 2022-12-31 | $42.50 Million | $-13.69 Million | -0.322x | -421.90% |
| 2021-12-31 | $51.42 Million | $-3.17 Million | -0.062x | +61.49% |
| 2020-12-31 | $241.35K | $-38.69K | -0.160x | -- |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more